Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
| Revenue (TTM) | $1.66B |
| Gross Profit (TTM) | $919.84M |
| EBITDA | $317.82M |
| Operating Margin | 10.10% |
| Return on Equity | 1.24% |
| Return on Assets | 2.86% |
| Revenue/Share (TTM) | $21.49 |
| Book Value | $13.71 |
| Price-to-Book | 0.45 |
| Price-to-Sales (TTM) | 0.63 |
| EV/Revenue | 0.572 |
| EV/EBITDA | 3.53 |
| Quarterly Earnings Growth (YoY) | 0.40% |
| Quarterly Revenue Growth (YoY) | 2.30% |
| Shares Outstanding | $77.77M |
| Float | $58.64M |
| % Insiders | 14.38% |
| % Institutions | 99.31% |
Volatility is currently contracting
PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, will present at the 2026 UBS Global Healthcare Conference on Monday, November 9, 2026, at 2:45 p.m. ET.
PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting, taking place October 31-November 4 in Washington, D.C. At this year's meeting, Integra will showcase its comprehensive neurosurgery portfolio through interactive educational experiences, hands-on training and technologies that support neurosurgeons across the continuum of care.
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Integra LifeSciences remains pressured by operational challenges, but restructuring and a returning CEO offer renewed turnaround potential. IART's Wound Reconstruction business continues to underperform, though upcoming product relaunches and market normalization could drive recovery. Valuation appears undemanding, with EBITDA margin expected to exceed 20% in 2025 and double-digit FCF margins possible by 2028.
Integra LifeSciences Holdings Corporation (IART) Q3 2026 Earnings Call Transcript
Integra LifeSciences NASDAQ: IART reported third-quarter revenue at the low end of its guidance range as a flooding-related disruption at its Cincinnati facility and slower-than-expected Tissue Reconstruction performance weighed on results. The company said strength in neurosurgery and international Specialty Surgery partially offset those pressures.
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.54 per share a year ago.
PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2026.
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal amount of 9.500% senior secured notes due 2033 (the “Notes”).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IART and any ticker you trade — then tracks every position and per-strategy win rate.
